Obese Rats Have Less of the Appetite-Suppressing Peptide Alpha-MSH in Their Brains
Genetically obese Zucker rats had reduced POMC mRNA in the arcuate nucleus and lower alpha-MSH in the paraventricular nucleus, revealing impaired appetite-suppressing peptide signaling in obesity.
Quick Facts
What This Study Found
Obese Zucker rats had reduced arcuate POMC mRNA and PVN alpha-MSH levels compared to lean controls, indicating impaired melanocortin satiety signaling as a driver of genetic obesity.
Key Numbers
How They Did This
Animal study comparing mRNA expression (in situ hybridization) of POMC, PENK, PDYN, and NPY in arcuate nucleus and peptide immunoreactivity in PVN between obese and lean Zucker rats at 18 weeks.
Why This Research Matters
Confirming that obesity involves deficient alpha-MSH satiety signaling supports melanocortin-based treatments. This pathway is now targeted by the obesity drug setmelanotide.
The Bigger Picture
Obesity isn't just about willpower — it involves measurable deficiencies in brain appetite-control peptides. The melanocortin system described here is now an FDA-approved obesity drug target.
What This Study Doesn't Tell Us
Zucker obesity is monogenic (leptin receptor mutation) and may not represent common human obesity. Peptide measurements at one timepoint don't capture dynamic regulation.
Questions This Raises
- ?Is POMC/alpha-MSH reduced in human obesity?
- ?Can melanocortin agonists restore satiety in obese individuals?
- ?Does the alpha-MSH deficit precede or follow obesity development?
Trust & Context
- Key Stat:
- Alpha-MSH reduced Obese rats had lower alpha-MSH in the brain region controlling satiety, suggesting obesity involves deficient natural appetite suppression
- Evidence Grade:
- Preliminary animal evidence in a well-established genetic obesity model with clear molecular findings.
- Study Age:
- Published in 2000. The melanocortin pathway has been validated as an obesity treatment target, with setmelanotide (a melanocortin-4 receptor agonist) FDA-approved for genetic obesity.
- Original Title:
- ARC POMC mRNA and PVN alpha-MSH are lower in obese relative to lean zucker rats.
- Published In:
- Brain research, 862(1-2), 11-6 (2000)
- Authors:
- Kim, E M(3), O'Hare, E, Grace, M K(3), Welch, C C, Billington, C J, Levine, A S
- Database ID:
- RPEP-00598
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Does obesity change brain chemistry?
Yes. This study shows obese rats have less of the natural appetite-suppressing peptide alpha-MSH in key brain areas. This means the brain's satiety signals are weaker in obesity, making it harder to stop eating.
Can this be treated with drugs?
Yes. The FDA has approved setmelanotide, which mimics alpha-MSH's appetite-suppressing action, for certain genetic forms of obesity. This validates the melanocortin pathway described in this study as a drug target.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00598APA
Kim, E M; O'Hare, E; Grace, M K; Welch, C C; Billington, C J; Levine, A S. (2000). ARC POMC mRNA and PVN alpha-MSH are lower in obese relative to lean zucker rats.. Brain research, 862(1-2), 11-6.
MLA
Kim, E M, et al. "ARC POMC mRNA and PVN alpha-MSH are lower in obese relative to lean zucker rats.." Brain research, 2000.
RethinkPeptides
RethinkPeptides Research Database. "ARC POMC mRNA and PVN alpha-MSH are lower in obese relative ..." RPEP-00598. Retrieved from https://rethinkpeptides.com/research/kim-2000-arc-pomc-mrna-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.